Jump to the top of the page

Showing 700 – 710 of 1307 results

  • Robert Metzger

    View biography for Robert Metzger, Senior Director.

  • Daniel N. Furhman

    View biography for Daniel N. Furhman, Managing Director, Wealth Advisor.

  • G2V Group and Freshstream Investment Partners transaction

    William Blair acted as the exclusive financial advisor to G2V Group, in connection with its pending sale to Freshstream Investments Partners.

  • William Blair Investment Management Named a 2024 Best Place to Work

    For the 12th year, William Blair Investment Management was named a Best Place to Work in Money Management by Pensions & Investments magazine.

  • Apellis Pharmaceuticals Inc Initiation

    William Blair initiated research coverage of Apellis Pharmaceuticals, Inc. (APLS $27.38), a global biopharmaceutical company focused on treating diseases by controlling the complement cascade.

  • Zeta Global Holdings Corp. Initiation

    William Blair initiated research coverage of Zeta Global Holdings Corp. (ZETA $7.99), a full stack enterprise marketing technology platform that helps businesses acquire, grow, and retain customers.

  • Poshmark Inc Initiation

    William Blair & Company initiated research coverage of Poshmark, Inc. (POSH $66.74), a technology platform and social marketplace where users can buy or sell new or used clothing, shoes, and accessories using its data-driven recommendation engine to drive transactions for its sellers.

  • Beam Therapeutics Inc Initiation

    William Blair & Company initiated research coverage of Beam Therapeutics Inc. (BEAM $19.01), a gene-editing company focused on developing innovative, precision medicines for serious diseases using the company’s proprietary base editing technology.

  • Poseida Therapeutics Inc Initiation

    William Blair & Company initiated research coverage of Poseida Therapeutics, Inc. (PSTX $12.98), a clinical-stage company focused on the development of genetically engineered T-cell therapies for the treatment of cancer and gene therapies for the treatment of rare genetic diseases.

  • Nikolay Djibankov

    View biography for Nikolay Djibankov, Vice President, Wealth Advisor.

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures